Gamma glutamyltransferase and risk of future dementia in middle-aged to older Finnish men: A new prospective cohort study

Alzheimer's and Dementia

Volumn 12, Issue 9, 2016, Pages 931-941

  Kunutsor, Setor K ^a   Laukkanen, Jari A ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Dementia; Gamma glutamyltransferase; Risk factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; COGNITION; COHORT ANALYSIS; DEMENTIA; DIABETES MELLITUS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FINN (CITIZEN); FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; SOCIAL STATUS; SYSTOLIC BLOOD PRESSURE; BLOOD; FINLAND; LONGITUDINAL STUDY; PROPORTIONAL HAZARDS MODEL;

ADULT; BIOMARKERS; DEMENTIA; FINLAND; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84969916110     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.03.003     Document Type: Article

References (35)

1. [1] Berr, C., Wancata, J., Ritchie, K., Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol 15 (2005), 463–471.
2. [2] Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H.M., Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3 (2007), 186–191.
3. [3] Zafrilla, P., Mulero, J., Xandri, J.M., Santo, E., Caravaca, G., Morillas, J.M., Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem 13 (2006), 1075–1083.
4. [4] Gackowski, D., Rozalski, R., Siomek, A., Dziaman, T., Nicpon, K., Klimarczyk, M., et al. Oxidative stress and oxidative DNA damage is characteristic for mixed Alzheimer disease/vascular dementia. J Neurol Sci 266 (2008), 57–62.
5. [5] Katayama, T., Hasebe, N., Angiotensin-receptor blockers, hypertension and Alzheimer disease–the entangled relationship. Circ J 77 (2013), 315–316.
6. [6] Roberson, E.D., Mucke, L., 100 years and counting: prospects for defeating Alzheimer's disease. Science 314 (2006), 781–784.
7. [7] Kunutsor, S., Apekey, T.A., Seddoh, D., Walley, J., Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol 43 (2014), 187–201.
8. [8] Kunutsor, S.K., Apekey, T.A., Khan, H., Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies. Atherosclerosis 236 (2014), 7–17.
9. [9] Kunutsor, S.K., Bakker, S.J., Kootstra-Ros, J.E., Gansevoort, R.T., Dullaart, R.P., Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis 238 (2014), 356–364.
10. [10] Breteler, M.M., Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21 (2000), 153–160.
11. [11] Emdin, M., Pompella, A., Paolicchi, A., Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 112 (2005), 2078–2080.
12. [12] von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61 (2008), 344–349.
13. [13] Salonen, J.T., Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 20 (1988), 46–50.
14. [14] Karppi, J., Kurl, S., Makikallio, T.H., Ronkainen, K., Laukkanen, J.A., Serum beta-carotene concentrations and the risk of congestive heart failure in men: A population-based study. Int J Cardiol 168 (2013), 1841–1846.
15. [15] Copeland, J.R., Dewey, M.E., Griffiths-Jones, H.M., A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med 16 (1986), 89–99.
16. [16] Salonen, J.T., Nyyssonen, K., Korpela, H., Tuomilehto, J., Seppanen, R., Salonen, R., High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 86 (1992), 803–811.
17. [17] Taylor, H.L., Jacobs, D.R. Jr., Schucker, B., Knudsen, J., Leon, A.S., Debacker, G., A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 31 (1978), 741–755.
18. [18] Lakka, T.A., Venalainen, J.M., Rauramaa, R., Salonen, R., Tuomilehto, J., Salonen, J.T., Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med 330 (1994), 1549–1554.
19. [19] Yang, S., Lynch, J.W., Raghunathan, T.E., Kauhanen, J., Salonen, J.T., Kaplan, G.A., Socioeconomic and psychosocial exposures across the life course and binge drinking in adulthood: population-based study. Am J Epidemiol 165 (2007), 184–193.
20. [20] Fibrinogen Studies Collaboration, Wood, A.M., White, I., Thompson, S.G., Lewington, S., Danesh, J., Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol 35 (2006), 1570–1578.
21. [21] Rosner, B., Willett, W.C., Spiegelman, D., Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error. Stat Med 8 (1989), 1051–1069 discussion 71–3.
22. [22] Kunutsor, S.K., Abbasi, A., Adler, A.I., Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Ann Epidemiol 24 (2014), 809–816.
23. [23] Jager, S., Jacobs, S., Kroger, J., Stefan, N., Fritsche, A., Weikert, C., et al. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One, 10, 2015, e0124749.
24. [24] Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 6, 2006, 33.
25. [25] van der Flier, W.M., Scheltens, P., Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76:Suppl 5 (2005), v2–v7.
26. [26] Kunutsor, S.K., Apekey, T.A., Seddoh, D., Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. Int J Clin Pract 69 (2015), 136–144.
27. [27] Kunutsor, S.K., Apekey, T.A., Hemelrijck, M.V., Calori, G., Perseghin, G., Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: Systematic review and meta-analysis. Int J Cancer 136 (2015), 1162–1170.
28. [28] Franzini, M., Corti, A., Martinelli, B., Del Corso, A., Emdin, M., Parenti, G.F., et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques–biochemical similarities with the circulating enzyme. Atherosclerosis 202 (2009), 119–127.
29. [29] Paolicchi, A., Emdin, M., Ghliozeni, E., Ciancia, E., Passino, C., Popoff, G., et al. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation, 109, 2004, 1440.
30. [30] McGeer, P.L., McGeer, E.G., The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126 (2013), 479–497.
31. [31] Zeevalk, G.D., Bernard, L.P., Nicklas, W.J., Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism. J Neurochem 70 (1998), 1421–1430.
32. [32] Perry, G., Nunomura, A., Hirai, K., Zhu, X., Perez, M., Avila, J., et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med 33 (2002), 1475–1479.
33. [33] Thoma, C., Day, C.P., Trenell, M.I., Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 56 (2012), 255–266.
34. [34] Rhone, D.P., White, F.M., Effects of storage in the cold on activity of gamma-glutamyltransferase in serum. Clin Chem 22 (1976), 103–104.
35. [35] Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16 (2011), 903–907.